| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6107960 | Journal of Hepatology | 2008 | 9 Pages |
Abstract
Peginterferon market uptake and access differed considerably across Europe, suggesting unequal access to optimised therapy. Besides budget restrictions, national surveillance and treatment policies should be considered as reasons for market access variation.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Beate Lettmeier, Nikolai Mühlberger, Ruth Schwarzer, Gaby Sroczynski, Davene Wright, Stefan Zeuzem, Uwe Siebert,